Loading...
Dyspepsia is a common symptom complex with a variety of underlying causes. Proton-pump inhibitor (PPI) therapy for dyspepsia is successful in some but not all patients.
To identify predictors of response to PPI therapy, investigators in Denmark conducted an industry-sponsored, double-blind, randomized, controlled trial involving 805 primary care patients with uninvestigated, upper gastrointestinal symptoms categorized as acid related by their physicians. Participants were randomized to receive 40 mg of esomeprazole or placebo daily for 2 weeks. The primary endpoint was response to PPI therapy, defined as absence of the patient's key complaint during the last 24 hours of treatment. Researchers used a modeling sample of 484 participants to ide…